Edition:
United States

ACADIA Pharmaceuticals Inc (ACAD.O)

ACAD.O on Nasdaq

27.98USD
1:24pm EST
Change (% chg)

$0.83 (+3.06%)
Prev Close
$27.15
Open
$27.68
Day's High
$28.78
Day's Low
$27.33
Volume
1,150,680
Avg. Vol
2,336,915
52-wk High
$42.49
52-wk Low
$16.64

Latest Key Developments (Source: Significant Developments)

Acadia Pharmaceuticals announces proposed public offering of common stock
Monday, 8 Aug 2016 04:01pm EDT 

Acadia Pharmaceuticals Inc : Acadia Pharmaceuticals announces proposed public offering of common stock .Acadia Pharmaceuticals Inc says that it intends to offer and sell, subject to market and other conditions, $200 million of its common stock.  Full Article

Acadia Pharmaceuticals reports Q2 2016 financial results
Thursday, 4 Aug 2016 04:05pm EDT 

Acadia Pharmaceuticals Inc : Acadia Pharmaceuticals reports second quarter 2016 financial results .Qtrly loss per share $0.63.  Full Article

UK's CMA could accept undertakings on Acadia's Priory Group deal
Thursday, 28 Jul 2016 07:09am EDT 

UK's CMA : To look at Acadia's undertakings offer in relation to acquisition of Priory Group No 1 Ltd in detail . Considers that undertaking offered, or a modified version of it, might be accepted .Now has until 23 September to decide whether to accept undertaking, with possibility to extend this timeframe to 18 november.  Full Article

ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
Tuesday, 5 Jan 2016 04:05pm EST 

ACADIA Pharmaceuticals Inc:t intends to offer and sell, subject to market and other conditions, $300,000,000 of shares of its common stock in an underwritten public offering.There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.BofA Merrill Lynch and J.P. Morgan Securities LLC are acting as the joint book-running managers for the offering.ACADIA intends to grant the underwriters a 30-day option to purchase an additional $45,000,000 of shares of its common stock.  Full Article

ACADIA Pharmaceuticals Inc Appoints Steve Davis as Chief Executive Officer
Thursday, 3 Sep 2015 07:01am EDT 

ACADIA Pharmaceuticals Inc:Board of Directors has appointed Steve Davis as President and Chief Executive Officer.Davis has been serving as ACADIA's Interim Chief Executive Officer since March 2015.Davis has also been appointed to the ACADIA Board of Directors.  Full Article

ACADIA Pharmaceuticals submits new drug application for NUPLAZID for the Treatment of Parkinson's Disease Psychosis
Thursday, 3 Sep 2015 07:00am EDT 

ACADIA Pharmaceuticals Inc:Announces it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for NUPLAZID (pimavanserin) for the treatment of psychosis associated with Parkinson's disease.  Full Article

ACADIA Pharmaceuticals Inc announces change in Chief Executive Officer
Wednesday, 11 Mar 2015 04:02pm EDT 

ACADIA Pharmaceuticals Inc:Says Uli Hacksell has retired as ACADIA's Chief Executive Officer and as member of Board of Directors, effective today.Says Steve Davis, Executive Vice President, Chief Financial Officer and Chief Business Officer of ACADIA, has been appointed as Interim Chief Executive Officer.Says Hacksell will remain as special advisor to company during this transition period.ACADIA's Board of Directors plans to initiate search for permanent Chief Executive Officer.  Full Article

ACADIA Pharmaceuticals Inc updates planned timing of NUPLAZIDTM NDA Submission
Wednesday, 11 Mar 2015 04:01pm EDT 

ACADIA Pharmaceuticals Inc:Provided an update on planned timing of its NUPLAZID(pimavanserin) New Drug Application (NDA) submission.Plans to submit its NUPLAZID NDA for treatment of Parkinson's disease psychosis in the second half of 2015.Says company had previously planned to submit NDA in Q1 of 2015.Decision to move back planned submission is based on additional time required to complete preparation of systems to support commercial manufacturing and supply and, in turn, to support the U.S. Food and Drug Administration's (FDA) review of NUPLAZID.Change in submission timing is not result of any change to NUPLAZID's clinical or safety profile, nor is it a result of any interaction with or request for information from FDA.  Full Article

BRIEF-Acadia Pharmaceuticals initiates phase II trial of Pimavanserin

* Acadia Pharmaceuticals initiates phase II trial of Pimavanserin for adjunctive treatment in patients with negative symptoms of schizophrenia Source text for Eikon: Further company coverage: